Clinical trial • Not applicable • Musculoskeletal
Gabapentin for Radicular leg pain
Not applicable trial of Gabapentin for Radicular leg pain.
Overview
- Trial Therapeutic Area
- Musculoskeletal
- Trial Disease
- Radicular leg pain
- Trial Stage
- Not applicable
- Drug Modality
- Small molecule|Other
Key dates
- Initial CTIS Submission Date
- 07-01-2024
- First CTIS Authorization Date
- 27-03-2024
Trial design
Placebo (GELATIN soft capsules), oral; product record shows max daily amount 9 U (characteristics '10').-controlled Not applicable trial across 3 sites in Denmark.
- Comparator
- Placebo (GELATIN soft capsules), oral; product record shows max daily amount 9 U (characteristics '10').
- Target Sample Size
- 200
- Trial Duration For Participant
- 42
Eligibility
Recruits 200 No vulnerable populations selected; participants are adults (age 18-70) and provide informed consent; assent is not applicable..
- Pregnancy Exclusion
- In fertile women: Pregnancy or lactation. Unwillingness to use effective contraceptive methods.
- Vulnerable Population
- No vulnerable populations selected; participants are adults (age 18-70) and provide informed consent; assent is not applicable.
Inclusion criteria
- {"criterion_text":"-Clinical diagnosis of radicular leg pain from the spine based upon the following (at least one symptom and one sign): a.\tSymptoms i.\tDermatomal leg pain pattern . ii.\tLeg pain below the knee and neuropathic leg symptom descriptors (burning, sticking, shooting, tingling, numbness) 3. b.\tSigns. i.\tReduced dermatomal sensibility. ii.\tAllodynia in dermatomal pattern (not diffuse). iii.\tReduced reflexes (focal). iv.\tParesis (strength less 5 on standard scale) in specific muscles in accordance with pain pattern (not pain induced paresis). v.\tMR-Scan with described root compression, which explain the pain. vi.\tPositive Straight leg test with pain below the knee (less than 45 deg) or by positive hip extension test)."}
- {"criterion_text":"-Symptom duration between 1 week and 6 months"}
- {"criterion_text":"-Average leg pain during last 24 h. Classified as at least moderate on a scale on severity (slight, moderate, severe and 4 on numeric rang score (NRS), with zero representing ‘no pain’ 10 worst imaginable pain)."}
- {"criterion_text":"-Age between 18 and 70 years"}
Exclusion criteria
- {"criterion_text":"-Known pulmonary disease with marked functional limitation."}
- {"criterion_text":"-Current treatment with anti-convulsants or anti-depressants for other conditions"}
- {"criterion_text":"-Opioids, muscle relaxants or anxiolytics (except one sleeping pill) intake last 4 days or treatment with any of these drugs evaluated to be indicated."}
- {"criterion_text":"-Previous back surgery during the preceding year"}
- {"criterion_text":"-Insufficient understanding of the Danish language to understand the written information and questionnaires (evaluated by the investigator)."}
- {"criterion_text":"-Cauda equina syndrome"}
- {"criterion_text":"-In fertile women: Pregnancy or lactation. Unwillingness to use effective contraceptive methods."}
- {"criterion_text":"-Central lumbar spinal stenosis symptomatology with bilateral walk related pain"}
- {"criterion_text":"-Other known pain condition of the lower extremities (e.g., knee or hip osteoarthrosis), which is deemed to influence leg pain scoring significantly"}
- {"criterion_text":"-Unable to use necessary electronic devices for the questionnaires and communication (Digital Post)."}
- {"criterion_text":"-Psychologic condition, which is evaluated likely to influence compliance negatively"}
- {"criterion_text":"-Known allergy or intolerance to Gabapentin or the content of the tablets."}
- {"criterion_text":"-Dementia"}
- {"criterion_text":"-Cancer (besides baso- or spinocellulary carcinoma) in the preceding year."}
- {"criterion_text":"-Severe heart disease NYHA class 3 or more."}
- {"criterion_text":"-Known moderate to severe kidney disease (eGFR < 50 ml/h)"}
- {"criterion_text":"-Poorly controlled diabetes (last measured HbA1c > 70 mmol/l)."}
- {"criterion_text":"-Previous treatment with anti-convulsants or anti-depressants for actual pain condition or treatment with these drugs evaluated to be indicated."}
- {"criterion_text":"-Steroid injection or corticosteroid treatment 6 weeks before start for the current pain condition"}
- {"criterion_text":"-Planed surgery for the radicular pain or major surgery next 3 month. Indication for evaluation by back surgeon or acute MR-scan ordered."}
Endpoints
Primary endpoints
- {"endpoint_text":"-Change in average leg pain intensity (measured on a numeric rating scale (NRS) from 0 to 10 over the last 24 hours) from baseline to week 6, based on least squares means and standard errors derived from the primary repeated measures mixed linear model, adjusted for baseline values.","definition_or_measurement_approach":"Measured on a numeric rating scale (NRS) from 0 to 10 over the last 24 hours; analysed using a primary repeated measures mixed linear model adjusted for baseline values to produce least squares means and standard errors, change from baseline to week 6."}
Secondary endpoints
- {"endpoint_text":"-Change from baseline to the 6 weeks assessment in aA (NRS - at 1, 2, 4 weeks)maximal leg pain, average back NRS pain and changes in NRS pain last 24 hours, pain related disability (ODIswestry), general health, (all 1, 2, 4, 6 weeks) with least squares means and standard errors derived estimates derived from the main repeated measures mixed linear model, adjusted for baseline values.","definition_or_measurement_approach":"Repeated measures assessments at weeks 1, 2, 4 and 6 using NRS for pain, Oswestry Disability Index for pain-related disability and general health measures; analysed using repeated measures mixed linear model adjusted for baseline producing least squares means and standard errors."}
- {"endpoint_text":"-Change in work status during the 6 week treatment period compared between Gabapentin and placebo.","definition_or_measurement_approach":"Comparison of work status change over the 6-week treatment period between treatment arms (method not further specified)."}
- {"endpoint_text":"-Occurence of AEs and SAEs in Gabapentin compared to placebo","definition_or_measurement_approach":"Collection and comparison of adverse events (AEs) and serious adverse events (SAEs) between Gabapentin and placebo groups."}
- {"endpoint_text":"-Intake of other analgesics compared between the Gabapentin and placebo group during a 6 weeks treatment period.","definition_or_measurement_approach":"Comparison of concomitant analgesic use between groups during the 6-week treatment period (collection of intake data)."}
Recruitment
- Digital Remote Recruitment
- Yes
- Planned Sample Size
- 200
- Recruitment Window Months
- 36
- Consent Approach
- Informed consent obtained from adult participants (age 18-70). Subject information and informed consent forms are listed among trial documents. Assent is not applicable.
Methods
- Planned recruitment via general practitioners (Denmark) — procedure referenced in assessment justification; sponsor did not sufficiently specify the procedure in SM-5 assessment.
- Planned recruitment via Elephant Health / digital messages (Denmark) — proposed digital recruitment channel; MREC did not approve the proposed recruitment via Elephant Health/digital messages.
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 200
Denmark
- Earliest CTIS Part Ii Submission Date
- 21-03-2024
- Latest Decision Or Authorization Date
- 10-06-2025
- Processing Time Days
- 446
- Number Of Sites
- 3
- Number Of Participants
- 200
Sites
- Site Name
- Region Midtjylland
- Department Name
- Diagnostisk Center, Hospitalsenhed Midt,
- Principal Investigator Name
- Vibeke Sørensen
- Principal Investigator Email
- vibesoer@rm.dk
- Contact Person Name
- Vibeke Sørensen
- Contact Person Email
- vibesoer@rm.dk
- Site Name
- Rigshospitalet
- Department Name
- Rygkirurgi, led og bindevævssygdomme
- Principal Investigator Name
- Signe Rifbjerg Madsen
- Principal Investigator Email
- signe.rifbjerg-madsen@regionh.dk
- Contact Person Name
- Signe Rifbjerg Madsen
- Contact Person Email
- signe.rifbjerg-madsen@regionh.dk
- Site Name
- Aalborg University Hospital
- Department Name
- Reumatologisk Afdeling, Klinik Medicin og Akut
- Principal Investigator Name
- Louise Jønholt
- Principal Investigator Email
- louise.joenholt@rn.dk
- Contact Person Name
- Louise Jønholt
- Contact Person Email
- louise.joenholt@rn.dk
Sponsor
Primary sponsor
- Full Name
- Rigshospitalet
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Third parties
- {"country":"Denmark","full_name":"GCP-enheden ved Københavns Universitetshospital","duties_or_roles":"Sponsor duties code 1","organisation_type":"Health care"}
Investigational products
- Investigational Product Name
- Gabapentin ”Orifarm”, hårde kapsler
- Active Substance
- Gabapentin
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- Authorised (marketingAuthNumber 37168; mrpNumber DK/H/1760/002)
- Maximum Dose
- 2700 mg/day
- Investigational Product Name
- GELATIN
- Active Substance
- Gelatin
- Modality
- Other
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- Not applicable/No marketing authorisation number listed
- Maximum Dose
- 9 U/day
Related trials
Other published trials that may interest you.